BioNTech Target of Unusually Large Options Trading (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) saw some unusual options trading activity on Tuesday. Stock traders bought 4,599 call options on the company. This represents an increase of 58% compared to the typical volume of 2,906 call options.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Bank of America upped their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Canaccord Genuity Group upped their target price on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Berenberg Bank assumed coverage on BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. Finally, Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $140.76.

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Planning Capital Management Corp increased its position in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. increased its position in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the period. GAMMA Investing LLC lifted its position in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC purchased a new position in shares of BioNTech during the second quarter valued at about $206,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Up 5.2 %

NASDAQ BNTX traded up $6.31 during trading on Tuesday, hitting $126.52. 679,224 shares of the company’s stock traded hands, compared to its average volume of 547,926. The firm has a market cap of $30.33 billion, a P/E ratio of -60.25 and a beta of 0.18. The stock has a fifty day moving average of $113.47 and a two-hundred day moving average of $102.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period last year, the company earned $0.73 EPS. As a group, sell-side analysts expect that BioNTech will post -3.72 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.